

Preparation: discs.

Comparison: moxonidine CRS.

TESTS

Related substances. Liquid chromatography (2.2.29).

Test solution. Dissolve 0.100 g of the substance to be examined in a mixture of equal volumes of *methanol R* and *water R* and dilute to 100.0 mL with the same mixture of solvents.

Reference solution (a). Dissolve 10.0 mg of moxonidine CRS in a mixture of equal volumes of *methanol R* and *water R* and dilute to 10.0 mL with the same mixture of solvents.

Reference solution (b). Dilute 1.0 mL of reference solution (a) to 100.0 mL with a mixture of equal volumes of *methanol R* and *water R*. Dilute 2.0 mL of this solution to 20.0 mL with a mixture of equal volumes of *methanol R* and *water R*.

Reference solution (c). Dissolve 5.0 mg of moxonidine impurity A CRS in a mixture of equal volumes of *methanol R* and *water R* and dilute to 100.0 mL with the same mixture of solvents.

Reference solution (d). Dilute 6.0 mL of reference solution (c) to 100.0 mL with a mixture of equal volumes of *methanol R* and *water R*.

Reference solution (e). Dilute 2.5 mL of reference solution (a) to 50.0 mL with reference solution (c).

Column:

- **size:** $l = 0.25$ m, $\varnothing = 4$ mm;
- **stationary phase:** base-deactivated octylsilyl silica gel for chromatography R (5 μ m);
- **temperature:** 40 °C.

Mobile phase: mix 136 volumes of acetonitrile R with 1000 volumes of a 3.48 g/L solution of sodium pentanesulfonate R previously adjusted to pH 3.5 with dilute sulfuric acid R.

Flow rate: 1.2 mL/min.

Detection: spectrophotometer at 230 nm.

Injection: 20 μ L; inject a blank, the test solution and reference solutions (b), (d) and (e).

Run time: twice the retention time of moxonidine.

Relative retentions with reference to moxonidine (retention time = about 11.6 min): impurity A = about 0.9; impurity B = about 1.7.

System suitability: reference solution (e):

- **resolution:** minimum of 2 between the peaks due to impurity A and moxonidine.

Limits:

- **impurity A:** not more than the area of the corresponding peak in the chromatogram obtained with reference solution (d) (0.3 per cent);
- **impurity B:** not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.3 per cent);
- **unspecified impurities:** for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent);
- **total:** not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent);
- **disregard limit:** 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent); disregard any peak observed with the blank run.

Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C for 3 h.

Sulfated ash (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.


Injection: test solution and reference solution (a).

Calculate the percentage content of $C_9H_{12}ClN_5O$ from the areas of the peaks and the declared content of moxonidine CRS.

IMPURITIES

Specified impurities: A, B.

Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): C, D.




- A. R4 = R6 = Cl: 4,6-dichloro-*N*-(imidazolidin-2-ylidene)-2-methylpyrimidin-5-amine (6-chloromoxonidine),
- B. R4 = R6 = OCH₃: *N*-(imidazolidin-2-ylidene)-4,6-dimethoxy-2-methylpyrimidin-5-amine (4-methoxymoxonidine),
- C. R4 = OH, R6 = OCH₃: 5-[(imidazolidin-2-ylidene)amino]-6-methoxy-2-methylpyrimidin-4-ol (4-hydroxymoxonidine),
- D. R4 = OH, R6 = Cl: 6-chloro-5-[(imidazolidin-2-ylidene)amino]-2-methylpyrimidin-4-ol (6-desmethoxymoxonidine).

01/2008:1450
corrected 6.0

MUPIROCIN

Mupirocinum



$C_{26}H_{44}O_9$
[12650-69-0]

M_r 500.6

DEFINITION

9-[(2*E*)-4-[(2*S*,3*R*,4*R*,5*S*)-3,4-Dihydroxy-5-[(2*S*,3*S*)-3-[(1*S*,2*S*)-2-hydroxy-1-methylpropyl]oxiranyl]methyl]tetrahydro-2*H*-pyran-2-yl]-3-methylbut-2-enoyl]oxy]nonanoic acid.

Substance produced by the growth of certain strains of *Pseudomonas fluorescens* or obtained by any other means.

Content: 93.0 per cent to 102.0 per cent (anhydrous substance).

CHARACTERS

Appearance: white or almost white powder.

Solubility: slightly soluble in water, freely soluble in acetone, in anhydrous ethanol and in methylene chloride.

It shows polymorphism (5.9).

IDENTIFICATION

Infrared absorption spectrophotometry (2.2.24).

Comparison: Ph. Eur. reference spectrum of mupirocin.

TESTS

pH (2.2.3): 3.5 to 4.0 for a freshly prepared saturated solution (about 10 g/L) in carbon dioxide-free water R.

Specific optical rotation (2.2.7): – 17 to – 21 (anhydrous substance).

Dissolve 0.50 g in *methanol R* and dilute to 10.0 mL with the same solvent.

Related substances. Liquid chromatography (2.2.29).

Solvent mixture. Mix 50 volumes of *methanol R* and 50 volumes of a 13.6 g/L solution of *sodium acetate R* adjusted to pH 4.0 with *acetic acid R*.

Test solution. Dissolve 50.0 mg of the substance to be examined in the solvent mixture and dilute to 10.0 mL with the solvent mixture.

Reference solution (a). Dilute 1.0 mL of the test solution to 50.0 mL with the solvent mixture.

Reference solution (b). Adjust 10 mL of reference solution (a) to pH 2.0 with *hydrochloric acid R* and allow to stand for 20 h.

Reference solution (c). Dissolve 25 mg of *mupirocin lithium CRS* in the solvent mixture and dilute to 200.0 mL with the solvent mixture.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: *octylsilyl silica gel for chromatography R* (5 μ m).

Mobile phase: mix 20 volumes of *water R*, 30 volumes of *tetrahydrofuran R* and 50 volumes of a 10.5 g/L solution of *ammonium acetate R* adjusted to pH 5.7 with *acetic acid R*.

Flow rate: 1 mL/min.

Detection: spectrophotometer at 240 nm.

Injection: 20 μ L.

Run time: 3.5 times the retention time of mupirocin.

Relative retention with reference to mupirocin: impurity C = about 0.75.

System suitability: reference solution (b):

- resolution: minimum 7.0 between the 2nd of the 2 peaks due to hydrolysis products and the peak due to mupirocin.

Limits:

- impurity C: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (a) (4 per cent);
- any other impurity: for each impurity, not more than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (1 per cent);
- total: not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (a) (6 per cent);
- disregard limit: 0.05 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.1 per cent).

Water (2.5.12): maximum 1.0 per cent, determined on 0.500 g.

ASSAY

Liquid chromatography (2.2.29).

Test solution. Dissolve 25.0 mg of the substance to be examined in 5 mL of *methanol R* and dilute to 200.0 mL with a 7.5 g/L solution of *ammonium acetate R* adjusted to pH 5.7 with *acetic acid R*.

Reference solution (a). Dissolve 25.0 mg of *mupirocin lithium CRS* in 5 mL of *methanol R* and dilute to 200.0 mL with a 7.5 g/L solution of *ammonium acetate R* adjusted to pH 5.7 with *acetic acid R*.

Reference solution (b). Adjust 10 mL of the test solution to pH 2.0 with *hydrochloric acid R* and allow to stand for 20 h.

Column:

- size: $l = 0.25$ m, $\varnothing = 4.6$ mm;
- stationary phase: *octylsilyl silica gel for chromatography R* (5 μ m).

Mobile phase: mix 19 volumes of *water R*, 32 volumes of *tetrahydrofuran R* and 49 volumes of a 10.5 g/L solution of *ammonium acetate R* adjusted to pH 5.7 with *acetic acid R*.

Flow rate: 1 mL/min.

Detection: spectrophotometer at 230 nm.

Injection: 20 μ L.

System suitability:

- resolution: minimum 7.0 between the 2nd of the 2 peaks due to hydrolysis products and the peak due to mupirocin in the chromatogram obtained with reference solution (b);
- repeatability: maximum relative standard deviation of 1.0 per cent after 6 injections of reference solution (a).


STORAGE

Protected from light.


IMPURITIES

Specified impurities: C.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, B, D, E, F.




A. 9-[[[(2E)-4-[(2S,3R,4R,5R)-3,4,5-trihydroxy-5-[[[(2S,3S)-3-[(1S,2S)-2-hydroxy-1-methylpropyl]oxiranyl]methyl]-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoyl]oxy]nonanoic acid (pseudomonic acid B),




B. 9-[[[(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[(2E,4R,5S)-5-hydroxy-4-methylhex-2-enyl]tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoyl]oxy]nonanoic acid (pseudomonic acid C),




C. (4E)-9-[[[(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[[(2S,3S)-3-[(1S,2S)-2-hydroxy-1-methylpropyl]oxiranyl]methyl]-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoyl]oxy]-non-4-enoic acid (pseudomonic acid D),



D. 9-[[[(2E)-4-[(2R,3aS,6S,7S)-2-[(2S,3S)-1,3-dihydroxy-2-methylbutyl]-7-hydroxyhexahydro-4H-furo[3,2-c]pyran-6-yl]-3-methylbut-2-enoyl]oxy]nonanoic acid,



- E. 9-[[[(2E)-4-[(2R,3RS,4aS,7S,8S,8aR)-3,8-dihydroxy-2-[(1S,2S)-2-hydroxy-1-methylpropyl]hexahydro-2H,5H-pyran[4,3-b]pyran-7-yl]-3-methylbut-2-enoyl]oxy]nonanoic acid,




- F. 7-[[[(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[[(2S,3S)-3-[(1S,2S)-2-hydroxy-1-methylpropyl]oxiranyl]methyl]tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoyl]oxy]heptanoic acid.

07/2010:1451

MUPIROCIN CALCIUM

Mupirocinum calcicum



$C_{52}H_{86}CaO_{18} \cdot 2H_2O$
[115074-43-6]

M_r 1075

DEFINITION

Calcium bis[9-[[[(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[[(2S,3S)-3-[(1S,2S)-2-hydroxy-1-methylpropyl]oxiranyl]methyl]tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoyl]oxy]nonanoate] dihydrate.

Substance produced by the growth of certain strains of *Pseudomonas fluorescens* or obtained by any other means.

Content: 93.0 per cent to 102.0 per cent (anhydrous substance).

CHARACTERS

Appearance: white or almost white powder.

Solubility: very slightly soluble in water, sparingly soluble in anhydrous ethanol and in methylene chloride.

IDENTIFICATION

- A. Infrared absorption spectrophotometry (2.2.24).

Comparison: Ph. Eur. reference spectrum of mupirocin calcium.

- B. It gives reaction (a) of calcium (2.3.1).

TESTS

Specific optical rotation (2.2.7): – 16 to – 20 (anhydrous substance).

Dissolve 0.50 g in *methanol R* and dilute to 10.0 mL with the same solvent.

Related substances. Liquid chromatography (2.2.29).

Solvent mixture. Mix 50 volumes of *methanol R* and 50 volumes of a 13.6 g/L solution of *sodium acetate R* adjusted to pH 4.0 with *acetic acid R*.

Test solution. Dissolve 50.0 mg of the substance to be examined in the solvent mixture and dilute to 10.0 mL with the solvent mixture.

Reference solution (a). Dilute 1.0 mL of the test solution to 50.0 mL with the solvent mixture.

Reference solution (b). Adjust 10 mL of reference solution (a) to pH 2.0 with *hydrochloric acid R* and allow to stand for 20 h.

Reference solution (c). Dissolve 25 mg of *mupirocin lithium CRS* in the solvent mixture and dilute to 200.0 mL with the solvent mixture.

Column:

- **size:** $l = 0.25$ m, $\varnothing = 4.6$ mm;
- **stationary phase:** *octylsilyl silica gel for chromatography R* (5 μ m).

Mobile phase: mix 20 volumes of *water R*, 30 volumes of *tetrahydrofuran R* and 50 volumes of a 10.5 g/L solution of *ammonium acetate R* adjusted to pH 5.7 with *acetic acid R*.

Flow rate: 1 mL/min.

Detection: spectrophotometer at 240 nm.

Injection: 20 μ L.

Run time: 3.5 times the retention time of mupirocin.

Relative retention with reference to mupirocin: impurity C = about 0.75.

System suitability: reference solution (b):

- **resolution:** minimum 7.0 between the 2nd of the 2 peaks due to hydrolysis products and the peak due to mupirocin.

Limits:

- **impurity C:** not more than 1.25 times the area of the principal peak in the chromatogram obtained with reference solution (a) (2.5 per cent);
- **any other impurity:** for each impurity, not more than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (1 per cent);
- **total:** not more than 2.25 times the area of the principal peak in the chromatogram obtained with reference solution (a) (4.5 per cent);
- **disregard limit:** 0.05 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.1 per cent).

Chlorides (2.4.4): maximum 0.5 per cent.

Dissolve 10.0 mg in a mixture of 1 mL of *dilute nitric acid R* and 15 mL of *methanol R*.

Water (2.5.12): 3.0 per cent to 4.5 per cent, determined on 0.500 g.

ASSAY

Liquid chromatography (2.2.29).

Test solution. Dissolve 25.0 mg of the substance to be examined in 5 mL of *methanol R* and dilute to 200.0 mL with a 7.5 g/L solution of *ammonium acetate R* adjusted to pH 5.7 with *acetic acid R*.

Reference solution (a). Dissolve 25.0 mg of *mupirocin lithium CRS* in 5 mL of *methanol R* and dilute to 200.0 mL with a 7.5 g/L solution of *ammonium acetate R* adjusted to pH 5.7 with *acetic acid R*.

Reference solution (b). Adjust 10 mL of the test solution to pH 2.0 with *hydrochloric acid R* and allow to stand for 20 h.

Column:

- **size:** $l = 0.25$ m, $\varnothing = 4.6$ mm;
- **stationary phase:** *octylsilyl silica gel for chromatography R* (5 μ m).

Mobile phase: mix 19 volumes of *water R*, 32 volumes of *tetrahydrofuran R* and 49 volumes of a 10.5 g/L solution of *ammonium acetate R* adjusted to pH 5.7 with *acetic acid R*.

Flow rate: 1 mL/min.

Detection: spectrophotometer at 230 nm.

Injection: 20 μ L.